3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Purpura, Thrombotic Thrombocytopenic
1
Purpura, Thrombocytopenic, Idiopathic
1
Neoplasms, Plasma Cell
1
Lymphoma
1
Leukemia
1
COVID-19
1
Interventions
Cyclophosphamide
59
fludarabine phosphate
52
Peripheral Blood Stem Cell Transplantation
40
Busulfan
39
Tacrolimus
35
Antilymphocyte Serum
34
Mycophenolic Acid
33
Radiotherapy
30
Filgrastim
28
Cyclosporine
25
Melphalan
24
Methotrexate
22
Whole-Body Irradiation
21
fludarabine
20
Methylprednisolone
17
Etoposide
16
Cord Blood Stem Cell Transplantation
15
sargramostim
9
Rituximab
9
Granulocyte Colony-Stimulating Factor
9
Cytarabine
9
Bortezomib
9
Alemtuzumab
9
Sirolimus
8
Epoetin Alfa
7
Psychiatric Rehabilitation
6
Prednisone
6
Flow Cytometry
6
Carmustine
6
Trimethoprim, Sulfamethoxazole Drug Combination
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Plasma Cell
×
ogalvibart
×
Lymphoid
×
Clear all
NCT05393999
2023-04-24
SABRE
Imperial College Healthcare NHS Trust
Phase 2
Withdrawn